Skip to main content

Advertisement

SpringerLink
Log in

Threats to validity of observational studies on disease-modifying antirheumatic drug therapies for rheumatoid arthritis: New aspects after the fall of the pyramid and the rise of new therapeutics

  • Invited Commentary
  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Wolfe F, Lassere M, van der HD, Stucki G, et al.: Preliminary core set of domains and reporting requirements for longitudinal observational studies in rheumatology. J Rheumatol 1999, 26:484–489.

    PubMed  CAS  Google Scholar 

  2. Bombardier C, Maetzel A: Pharmacoeconomic evaluation of new treatments: efficacy versus effectiveness studies? Ann Rheum Dis 1999, 58(suppl):I82-I85.

    Article  PubMed  Google Scholar 

  3. Fries JF: Reevaluating the therapeutic approach to rheumatoid arthritis: the “sawtooth” strategy. J Rheumatol 1990, 22(suppl):12–15.

    CAS  Google Scholar 

  4. Aletaha D, Smolen JS: The rheumatoid arthritis patient in the clinic: comparing more than 1300 consecutive DMARD courses. Rheumatology (Oxford) 2002, 41:1367–1374.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Rheumatology, Department of Internal Medicine III, University of Vienna, Vienna General Hospital, Waehringer Guertel 18-20, A-1090, Vienna, Austria

    Daniel Aletaha MD

Authors
  1. Daniel Aletaha MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Josef S. Smolen MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Aletaha, D., Smolen, J.S. Threats to validity of observational studies on disease-modifying antirheumatic drug therapies for rheumatoid arthritis: New aspects after the fall of the pyramid and the rise of new therapeutics. Curr Rheumatol Rep 5, 409–412 (2003). https://doi.org/10.1007/s11926-003-0048-y

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-003-0048-y

Keywords

Search

Navigation